Outlook Therapeutics (OTLK) 10-Q 13 Aug 21 2021 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Jun. 30, 2021	Aug. 11, 2021
Document And Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Entity File Number	001-37759
Entity Registrant Name	OUTLOOK THERAPEUTICS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	38-3982704
Entity Address, Address Line One	485 Route 1 South
Entity Address, Address Line Two	Building F, Suite 320
Entity Address, City or Town	Iselin
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08830
City Area Code	609
Local Phone Number	619-3990
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		175,341,173
Entity Central Index Key	0001649989
Current Fiscal Year End Date	--09-30
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Amendment Flag	false
Common Stock
Document And Entity Information
Title of 12(b) Security	Common Stock
Trading Symbol	OTLK
Security Exchange Name	NASDAQ
Series A Warrants
Document And Entity Information
Title of 12(b) Security	Series A Warrants
Trading Symbol	OTLKW
Security Exchange Name	NASDAQ

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2021	Sep. 30, 2020
Current assets:
Cash	$ 19,692,035	$ 12,535,986
Prepaid expenses and other current assets	12,205,296	5,407,882
Total current assets	31,897,331	17,943,868
Property and equipment, net	204,531	327,249
Operating lease right-of-use assets, net	121,197	166,986
Equity method investment	464,654
Other assets	194,355	1,294,448
Total assets	32,882,068	19,732,551
Current liabilities:
Current portion of long-term debt	11,549,425	50,285
Current portion of finance lease liabilities	27,459	29,778
Current portion of operating lease liabilities	41,720	187,486
Stockholder notes		3,612,500
Accounts payable	2,671,501	2,394,818
Accrued expenses	3,491,944	7,757,310
Income taxes payable	1,856,629	1,856,629
Total current liabilities	19,638,678	15,888,806
Long-term debt		904,200
Finance lease liabilities	21,703	42,482
Operating lease liabilities	38,203
Warrant liability	434,248	70,772
Total liabilities	20,132,832	16,906,260
Commitments and contingencies (Note 9)
Convertible preferred stock:
Total convertible preferred stock
Stockholders' equity:
Preferred stock, value
Common stock, par value $0.01 per share; 325,000,000 shares authorized; 174,813,326 shares issued and outstanding at June 30, 2021 and 127,183,109 shares issued and outstanding at September 30, 2020	1,748,133	1,271,831
Additional paid-in capital	340,479,991	291,274,366
Accumulated deficit	(329,478,888)	(289,719,906)
Total stockholders' equity	12,749,236	2,826,291
Total liabilities, convertible preferred stock and stockholders' equity	32,882,068	19,732,551
Series A convertible preferred stock
Convertible preferred stock:
Total convertible preferred stock
Series A-1 convertible preferred stock
Convertible preferred stock:
Total convertible preferred stock
Series B convertible preferred stock
Stockholders' equity:
Preferred stock, value

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Jun. 30, 2021	Sep. 30, 2020
Preferred stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	7,300,000	7,300,000
Preferred stock, shares issued	0	0
Preferred stock shares outstanding	0	0
Common stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	325,000,000	325,000,000
Common stock, shares issued	174,813,326	127,183,109
Common stock, shares outstanding	174,813,326	127,183,109
Series A convertible preferred stock
Convertible stock, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible preferred stock, shares authorized	1,000,000	1,000,000
Convertible preferred stock, shares issued	0	0
Convertible preferred stock outstanding	0	0
Series A-1 convertible preferred stock
Convertible stock, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible preferred stock, shares authorized	200,000	200,000
Convertible preferred stock, shares issued	0	0
Convertible preferred stock outstanding	0	0
Series B convertible preferred stock
Preferred stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,500,000	1,500,000
Preferred stock, shares issued	0	0
Preferred stock shares outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Operating expenses:
Research and development	$ 8,545,279	$ 8,488,143	$ 29,023,253	$ 18,718,659
General and administrative	2,929,717	3,286,739	9,267,962	7,580,638
Impairment of property and equipment		104,296		527,624
Total operating expenses	11,474,996	11,879,178	38,291,215	26,826,921
Loss from operations	(11,474,996)	(11,879,178)	(38,291,215)	(26,826,921)
Loss on equity method investment	435,346		435,346
Interest expense, net	256,873	443,624	666,945	1,737,440
(Gain) loss on extinguishment of debt		(6,164,284)		1,896,296
Change in fair value of redemption feature				(1,796,982)
Change in fair value of warrant liability	29,332	127,506	363,476	(74,636)
Loss before income taxes	(12,196,547)	(6,286,024)	(39,756,982)	(28,589,039)
Income tax expense (benefit)		(3,271,157)	2,000	(3,271,157)
Net loss	(12,196,547)	(3,014,867)	(39,758,982)	(25,317,882)
Series A-1 convertible preferred stock dividends and related settlement				(166,133)
Deemed dividend upon modification of warrants				(3,140,009)
Deemed dividend upon amendment of the terms of the Series A-1 convertible preferred stock				(10,328,118)
Net loss attributable to common stockholders	$ (12,196,547)	$ (3,014,867)	$ (39,758,982)	$ (38,952,142)
Per share information:
Net loss per share of common stock, basic (in dollars per share)	$ (0.07)	$ (0.03)	$ (0.27)	$ (0.69)
Net loss per share of common stock, diluted (in dollars per share)	$ (0.07)	$ (0.03)	$ (0.27)	$ (0.69)
Weighted average shares outstanding, basic (in shares)	168,420,675	90,757,825	146,860,652	56,089,036
Weighted average shares outstanding, diluted (in shares)	168,420,675	90,757,825	146,860,652	56,089,036

Consolidated Statements of Conv

Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)	Preferred StockSeries A-1 convertible preferred stock	Common StockMTTR, LLC ("MTTR")	Common Stock	Additional Paid-in CapitalMTTR, LLC ("MTTR")	Additional Paid-in Capital	Accumulated Deficit	Series A-1 convertible preferred stock	Total
Balance at Sep. 30, 2019	$ 5,359,404		$ 286,100		$ 238,064,947	$ (254,480,408)		$ (16,129,361)
Balance, beginning (in shares) at Sep. 30, 2019	66,451		28,609,995
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with exercise of warrants			$ 130,034		1,008,866			1,138,900
Issuance of common stock in connection with exercise of warrants (in shares)			13,003,414
Issuance of common stock in connection with conversion of stockholder notes and interest			$ 14,753		1,533,673			1,548,426
Issuance of common stock in connection with conversion of stockholder notes and interest (in shares)			1,475,258
Sale of common stock, net of issuance costs		$ 72,447	$ 344,665	$ (72,447)	34,004,060			34,348,725
Sale of common stock, net of issuance costs (in shares)		7,244,739	34,466,467
Issuance of common stock in connection with conversion of senior secured notes and interest			$ 122,015		7,872,479			$ 7,994,494
Issuance of common stock in connection with conversion of senior secured notes and interest (in shares)			12,201,461
Issuance of vested restricted stock units			$ 1		(1)
Issuance of vested restricted stock units (in shares)			109					109
Series A-1 convertible preferred stock dividends and related settlement	$ 166,133				(166,133)			$ (166,133)
Series A-1 convertible preferred stock dividends and related settlement (in shares)	1,661						1,661
Conversion of Series A-1 convertible preferred stock to common stock	$ (5,525,537)		$ 293,586		5,231,951			5,525,537
Conversion of Series A-1 convertible preferred stock to common stock (in shares)	(68,112)		29,358,621
Stock-based compensation expense					2,022,736			2,022,736
Net loss						(25,317,882)		(25,317,882)
Balance at Jun. 30, 2020			$ 1,263,601		289,500,131	(279,798,290)		10,965,442
Balance, ending (in shares) at Jun. 30, 2020			126,360,064
Balance at Mar. 31, 2020			$ 897,512		255,361,229	(276,783,423)		(20,524,682)
Balance, beginning (in shares) at Mar. 31, 2020			89,751,192
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Sale of common stock, net of issuance costs			$ 244,074		24,907,703			25,151,777
Sale of common stock, net of issuance costs (in shares)			24,407,411
Issuance of common stock in connection with conversion of senior secured notes and interest			$ 122,015		7,872,479			7,994,494
Issuance of common stock in connection with conversion of senior secured notes and interest (in shares)			12,201,461
Stock-based compensation expense					1,358,720			1,358,720
Net loss						(3,014,867)		(3,014,867)
Balance at Jun. 30, 2020			$ 1,263,601		289,500,131	(279,798,290)		10,965,442
Balance, ending (in shares) at Jun. 30, 2020			126,360,064
Balance at Sep. 30, 2020			$ 1,271,831		291,274,366	(289,719,906)		2,826,291
Balance, beginning (in shares) at Sep. 30, 2020			127,183,109
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with exercise of warrants			$ 38,153		3,547,656			3,585,809
Issuance of common stock in connection with exercise of warrants (in shares)			3,815,304
Sale of common stock, net of issuance costs			$ 438,149		42,175,197			42,613,346
Sale of common stock, net of issuance costs (in shares)			43,814,913
Stock-based compensation expense					3,482,772			3,482,772
Net loss						(39,758,982)		(39,758,982)
Balance at Jun. 30, 2021			$ 1,748,133		340,479,991	(329,478,888)		12,749,236
Balance, ending (in shares) at Jun. 30, 2021			174,813,326
Balance at Mar. 31, 2021			$ 1,736,058		336,197,455	(317,282,341)		20,651,172
Balance, beginning (in shares) at Mar. 31, 2021			173,605,807
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Sale of common stock, net of issuance costs			$ 12,075		3,084,152			3,096,227
Sale of common stock, net of issuance costs (in shares)			1,207,519
Stock-based compensation expense					1,198,384			1,198,384
Net loss						(12,196,547)		(12,196,547)
Balance at Jun. 30, 2021			$ 1,748,133		$ 340,479,991	$ (329,478,888)		$ 12,749,236
Balance, ending (in shares) at Jun. 30, 2021			174,813,326

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
OPERATING ACTIVITIES
Net loss	$ (39,758,982)	$ (25,317,882)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	211,466	473,920
Loss on extinguishment of debt		1,896,296
Non-cash interest expense	640,215	235,636
Stock-based compensation	3,482,772	2,022,736
Change in fair value of redemption feature		(1,796,982)
Change in fair value of warrant liability	363,476	(74,636)
Impairment of property and equipment		527,624
Gain on settlement of lease termination obligation	(552,340)
Loss on lease termination		680,017
Loss on equity method investment	435,346
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(6,904,417)	676,564
Other assets	298,523	(84,120)
Operating lease liability	(140,272)	(122,193)
Accounts payable	194,029	900,030
Accrued expenses	(3,532,940)	215,175
Other liabilities		55,587
Net cash used in operating activities	(45,263,124)	(19,712,228)
INVESTING ACTIVITIES
Investment in joint venture		(900,000)
Net cash used in investing activities		(900,000)
FINANCING ACTIVITIES
Proceeds from the sale of common stock, net of offering costs	42,514,237	34,739,271
Proceeds from debt	10,000,000	904,200
Payment of debt issuance costs	(8,032)
Proceeds from exercise of common stock warrants	3,585,809	1,138,900
Payments of finance lease obligations	(23,098)	(196,959)
Repayment of debt	(3,649,743)	(35,632)
Net cash provided by financing activities	52,419,173	36,549,780
Net increase in cash	7,156,049	15,937,552
Cash at beginning of period	12,535,986	8,015,528
Cash at end of period	19,692,035	23,953,080
Supplemental disclosure of cash flow information
Cash paid for interest	17,915	910,503
Accrued interest settled by conversion into common stock		1,531,004
Supplemental schedule of non-cash financing activities:
Senior secured notes principal converted into common stock		7,033,950
Unsecured notes and accrued interestprincipal converted into common stock		(977,966)
Issuance of exchange notes at estimated fair value		7,050,206
Issuance of redemption feature at estimated fair value		8,264,451
Series A-1 convertible preferred stock dividends and related settlement		166,133
Deferred offering costs and common stock issuance costs in accounts payable and accrued expenses	$ 82,654	$ 390,546

Organization and Description of

Organization and Description of Business	9 Months Ended
	Jun. 30, 2021
Organization and Description of Business
Organization and Description of Business	1. Organization and Description of Business Outlook Therapeutics, Inc. (“Outlook” or the “Company”) was incorporated in New Jersey on January 5, 2010, started operations in July 2011, reincorporated in Delaware by merging with and into a Delaware corporation in October 2015 and changed its name to “Outlook Therapeutics, Inc.” in November 2018. The Company is a late clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, an ophthalmic formulation of bevacizumab for use in retinal indications. The Company is based in Iselin, New Jersey. ​ The Company has been actively monitoring the novel coronavirus (“COVID-19”) pandemic and its impact globally. Given the Company’s current infrastructure needs and current strategy, the Company was able to transition to remote working with limited impact on productivity, as shelter-in-place and similar government orders were imposed. All development activities are currently active in support of the Company’s Biologics License Application (“BLA”) registration program for ONS-5010 for wet age-related macular degeneration (“wet AMD”). ​ The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19. Management believes the financial results for the nine months ended June 30, 2021 were not significantly impacted by COVID-19. ​

Liquidity

Liquidity	9 Months Ended
	Jun. 30, 2021
Liquidity
Liquidity	2. Liquidity The Company has incurred substantial losses and negative cash flows from operations since its inception. As of June 30, 2021, the Company had $10.7 million of principal and accrued interest due under an unsecured promissory note maturing on January 1, 2022, and a $0.9 million loan granted pursuant to the Paycheck Protection Program (the “PPP”) of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), which matures on May 2, 2022. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying unaudited interim consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The unaudited interim consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. In July 2021, the Company sold 527,216 shares of common stock under its "at-the-market" equity offering program (the "ATM Offering"). The Company generated $1.3 million in net proceeds from the ATM Offering after payment of fees to the sales agent of $43,000. Management believes that the Company’s existing cash as of June 30, 2021, together with the $1.3 million in net proceeds from the sale of shares of common stock under the ATM Offering in July 2021, will be sufficient to fund its operations through December 2021. Substantial additional financing will be needed by the Company to fund its operations in the future and to commercially develop ONS-5010 and any other product candidates. Management is currently evaluating different strategies to obtain the required funding for future operations. These strategies may include but are not limited to proceeds from potential licensing and/or marketing arrangements with pharmaceutical companies, the issuance of equity securities, and the issuance of additional debt, potential collaborations and revenues from potential future product sales, if any. There can be no assurance that these future funding efforts will be successful. The Company’s future operations are highly dependent on a combination of factors, including (i) the timely and successful completion of additional financing discussed above; (ii) the Company’s ability to complete revenue-generating partnerships with pharmaceutical companies; (iii) the success of its research and development; (iv) the development of competitive therapies by other biotechnology and pharmaceutical companies, and, ultimately; (v) regulatory approval and market acceptance of the Company’s proposed future products.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Jun. 30, 2021
Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation and Summary of Significant Accounting Policies	3. Basis of Presentation and Summary of Significant Accounting Policies Basis of presentation The accompanying unaudited interim consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). In the opinion of management, the accompanying unaudited interim consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s financial position as of June 30, 2021 and its results of operations for the three and nine months ended June 30, 2021 and 2020, cash flows for the nine months ended June 30, 2021 and 2020, and convertible preferred stock and stockholders’ equity (deficit) for the three and nine months ended June 30, 2021 and 2020. Operating results for the three and nine months ended June 30, 2021 are not necessarily indicative of the results that may be expected for the full year ending September 30, 2021. The unaudited interim consolidated financial statements, presented herein, do not contain the required disclosures under GAAP for annual consolidated financial statements. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended September 30, 2020 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on December 23, 2020 and amended on January 28, 2021. Use of estimates The preparation of the unaudited interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the unaudited interim consolidated financial statements, including as a result of the ongoing COVID-19 pandemic, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary. Equity method investment The Company accounts for equity investments where it owns a non-controlling interest, but has the ability to exercise significant influence, under the equity method of accounting. Under the equity method of accounting, the original cost of the investment is adjusted for the Company’s share of equity in the earnings or loss of the equity investee and reduced by dividends and distributions of capital received, unless the fair value option is elected, in which case the investment balance is marked to fair value each reporting period and the impact of changes in fair value of the equity investment are reported in earnings. The Company has not elected the fair value option. The Company assesses its investment for other-than-temporary impairment when events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable and recognize an impairment loss to adjust the investment to its then-current fair value. Net loss per share Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. For purposes of calculating diluted loss per common share, the denominator includes both the weighted average common shares outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and non-vested restricted stock unit (“RSU”) awards using the treasury stock method. For all periods presented, there is no difference in the number of shares used to compute basic and diluted shares due to the Company’s loss. The following table sets forth the computation of basic earnings per share and diluted earnings per share: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended June 30, ​ Nine months ended June 30, ​ 2021 2020 2021 2020 Net loss attributable to common stockholders ​ $ (12,196,547) ​ $ (3,014,867) ​ $ (39,758,982) ​ $ (38,952,142) Common stock outstanding (weighted average) ​ ​ 168,420,675 ​ ​ 90,757,825 ​ ​ 146,860,652 ​ ​ 56,089,036 Basic and diluted net loss per share ​ $ (0.07) ​ $ (0.03) ​ $ (0.27) ​ $ (0.69) ​ The following potentially dilutive securities (in common stock equivalents) have been excluded from the computation of diluted weighted-average shares outstanding as of June 30, 2021 and 2020, as they would be antidilutive: ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, ​ 2021 2020 Performance-based stock units ​ 2,470 ​ 2,470 Stock options ​ 12,110,015 ​ 2,238,470 Common stock warrants ​ 5,129,460 ​ 7,051,857 ​ Recently issued accounting pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) Disclosure Framework — Changes to the Disclosure Requirements for Fair Value Measurement ​ In January 2020, FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Jun. 30, 2021
Fair Value Measurements
Fair Value Measurements	4. Fair Value Measurements Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: ● Level 1 - Quoted prices in active markets for identical assets or liabilities. ● Level 2 - Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. ● Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 ​ (Level 1) (Level 2) (Level 3) Liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrant liability ​ $ — ​ $ — ​ $ 434,248 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2020 ​ ​ (Level 1) (Level 2) (Level 3) Liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrant liability ​ $ — ​ $ — ​ $ 70,772 ​ The table presented below is a summary of changes in the fair value of the Company’s Level 3 valuation for the warrant liability and redemption feature for the nine months ended June 30, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrants Balance at October 1, 2020 ​ $ 70,772 Change in fair value ​ ​ 363,476 Balance at June 30, 2021 ​ $ 434,248 ​ The warrants issued in connection with the convertible senior secured notes (see Note 8) are classified as liabilities on the accompanying consolidated balance sheets as the warrants include cash settlement features at the option of the holders under certain circumstances. The warrant liability is revalued each reporting period with the change in fair value recorded in the accompanying consolidated statements of operations until the warrants are exercised or expire. The fair value of the warrant liability is estimated using the Black-Scholes option pricing model using the following assumptions: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 September 30, 2020 Risk-free interest rate ​ ​ 0.59 % ​ ​ 0.24 % Remaining contractual term of warrant ​ ​ 3.6 years ​ ​ 4.4 years Expected volatility ​ ​ 98.3 % ​ ​ 94.7 % Annual dividend yield ​ ​ — % ​ ​ — % Fair value of common stock ​ $ 2.49 per ​ $ 0.72 per ​ Fair Value of Other Financial Instruments ​ At June 30, 2021, the carrying values of the PPP loan and unsecured promissory note approximate their respective fair values due to their short duration to maturity.

Property and Equipment, Net

Property and Equipment, Net	9 Months Ended
	Jun. 30, 2021
Property and Equipment, Net
Property and Equipment, Net	5. Property and Equipment, Net Property and equipment, net, consists of: ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 September 30, 2020 Laboratory equipment ​ $ 1,067,351 ​ $ 1,067,351 Less: accumulated depreciation and amortization ​ ​ (862,820) ​ ​ (740,102) ​ ​ $ 204,531 ​ $ 327,249 ​ Depreciation expense was $40,906 and $50,959 for the three months ended June 30, 2021 and 2020, respectively and $122,718 and $178,510 for the nine months ended June 30, 2021 and 2020, respectively.

Other Assets

Other Assets	9 Months Ended
	Jun. 30, 2021
Other Assets.
Other Assets	6. Other Assets ​ Other assets consist of: ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 September 30, 2020 Investment in PRC joint venture ​ $ — ​ $ 900,000 Other assets ​ ​ 194,355 ​ ​ 394,448 ​ ​ $ 194,355 ​ $ 1,294,448 ​ In connection with the execution of a stock purchase agreement with Syntone Ventures LLC (“Syntone Ventures”), the U.S. based affiliate of Syntone Technologies Group Co. Ltd. (“Syntone PRC”) on May 22, 2020, the Company and Syntone PRC entered into a joint venture agreement pursuant to which they agreed to form a People’s Republic of China (“PRC”) joint venture, Beijing Syntone Biopharma Ltd (“Syntone”), that is 80% owned by Syntone PRC and 20% owned by the Company. As the Company can exert significant influence over, but does not control, Syntone’s operations through voting rights or representation on Syntone’s board of directors, the Company accounts for this investment using the equity method of accounting. Upon formation of Syntone in April 2021, the Company entered into a royalty-free license with Syntone for the development, commercialization and manufacture of ONS-5010 in the greater China market, which includes Hong Kong, Taiwan and Macau. The Company made the initial investment of $900,000 in June 2020 which was included in other assets at September 30, 2020 and upon formation of Syntone in April 2021, the Company reclassified the investment to equity method investment in the accompanying consolidated balance sheets. The Company expects to be required to make an additional capital contribution to Syntone of approximately $2.1 million, which will be made within four years after the establishment date in accordance with the development plan contemplated in the license agreement or on such other terms within such four-year period. The maximum exposure to a loss as a result of the Company’s involvement in Syntone is limited to the initial investment and the future capital contributions of approximately $2.1 million.

Accrued Expenses

Accrued Expenses	9 Months Ended
	Jun. 30, 2021
Accrued Expenses
Accrued Expenses	7. Accrued Expenses Accrued expenses consists of: ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 September 30, 2020 Compensation ​ $ 452,278 ​ $ 579,618 Severance and related costs ​ ​ — ​ ​ 9,521 Research and development ​ ​ 2,837,663 ​ ​ 2,890,333 Interest payable ​ ​ 10,454 ​ ​ 3,691 Professional fees ​ ​ 43,302 ​ ​ 132,085 Lease termination obligation ​ ​ — ​ ​ 3,971,111 Other accrued expenses ​ ​ 148,247 ​ ​ 170,951 ​ ​ $ 3,491,944 ​ $ 7,757,310 ​

Debt

Debt	9 Months Ended
	Jun. 30, 2021
Debt
Debt	8. Debt ​ Debt consists of: ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 September 30, 2020 Unsecured promissory note ​ $ 10,734,986 ​ $ — Paycheck Protection Program term loan ​ ​ 904,200 ​ ​ 904,200 Equipment loans ​ ​ 13,042 ​ ​ 50,285 Total debt ​ ​ 11,652,228 ​ ​ 954,485 Less: unamortized loan costs ​ ​ (102,803) ​ ​ — Total debt, net of unamortized loan costs ​ ​ 11,549,425 ​ ​ 954,485 Less: current portion ​ ​ (11,549,425) ​ ​ (50,285) Long-term debt ​ $ — ​ $ 904,200 ​ ​ Unsecured promissory note ​ On November 5, 2020, the Company received $10.0 million in net proceeds from issuance of an unsecured promissory note with face amount of $10.2 million. Debt issuance costs totaling $228,032 are recorded as debt discount and are deducted from the principal in the accompanying consolidated balance sheets. The debt discount is amortized as a component of interest expense over the 14-month term of the underlying debt using the effective interest method. The note bears interest at a rate of 7.5% per annum and matures January 1, 2022. The Company may prepay all or a portion of the note at any time by paying 105% of the outstanding balance elected for pre-payment. During the three and nine months ended June 30, 2021, the Company recognized $248,186, and $640,215, respectively, of interest expense related to the unsecured promissory note. ​ Paycheck Protection Program term loan ​ On May 4, 2020, the Company received $904,200 in proceeds from a loan granted pursuant to the PPP of the CARES Act. The PPP term loan is evidenced by a promissory note containing the terms and conditions for repayment of the PPP term loan. The PPP term loan provides for an initial six-month deferral of payments and any amount owed on the loan has a two-year maturity (May 2022), with an interest rate of 1% per annum. Commencing October 15, 2021, the Company is required to pay the lender equal monthly payments of principal and interest as required to fully amortize any principal amount outstanding on the PPP term loan as of October 15, 2021 by May 2, 2022. The Company has the right to prepay any amounts outstanding under this loan at any time and from time to time, in whole or in part, without penalty. Aggregate interest expense on the PPP loan for the three and nine months ended June 30, 2021 was $2,279, and $6,763, respectively. ​ Senior secured notes ​ In December 2019, the Company entered into an exchange agreement with the holders of its $7,254,077 outstanding aggregate principal amount and accrued interest of senior secured notes (the “Old Senior Notes”) originally issued pursuant to the certain Note and Warrant Purchase Agreement dated December 22, 2017, as amended on April 13, 2017, November 5, 2018, and June 28, 2019 (the “Exchange Agreement”). Pursuant to the Exchange Agreement, the holders of the Old Senior Notes exchanged the entire outstanding principal and accrued interest for new senior secured notes having an aggregate outstanding original principal amount of $7,589,027 which included an aggregate exchange fee of $334,950. The new senior secured notes were substantially similar to the Old Senior Notes, as amended through the date of the Exchange Agreement, bore interest at a rate of 12.0% per annum and would have matured December 31, 2020 (subject to extension to June 30, 2021 at the Company’s option upon payment of an extension fee equal to 3% of the outstanding balance and being in compliance with applicable Nasdaq listing requirements). The new senior secured notes were convertible, at the option of the holder, beginning April 1, 2020, into shares of the Company’s common stock at a conversion price equal to 90% of the two lowest closing bid prices in the 20 trading days immediately preceding such conversion, subject to a floor price of $0.232 per share. The conversion feature was determined to be a redemption feature and was bifurcated from the debt instrument. The estimated fair value of the redemption feature was $8,264,451 at issuance. The Exchange Agreement was accounted for as an extinguishment of debt. The Company recognized a loss on extinguishment of convertible senior secured notes for the Exchange Agreement during the three months ended December 31, 2019 of $8,060,580, which amount was equal to the excess fair value of the notes and bifurcated redemption feature over the notes’ net carrying value. The fair value of the redemption feature was estimated by using a Monte Carlo simulation model and a with-and-without perspective, where the fair value of debt instrument was measured with the derivative and without the derivative and the difference is the implied fair value of the redemption feature. The value of the debt instrument with the redemption feature depended on the daily stock price path followed by the Company’s common stock price. This model simulated daily common stock prices from the issuance date through the maturity date for the debt instrument. At issuance, the Company utilized a volatility estimate of 130% based upon the observed historical volatility of both the Company and peer group for 1-year and 2-year periods. Risk-free interest rate was based upon US treasury yields. During the year ended September 30, 2020, the holder of the new senior secured notes converted the entire outstanding principal and accrued interest and as of September 30, 2020, there were no longer any new senior secured notes outstanding. Aggregate interest expense on the Old Senior Notes and the new senior secured notes for the three and nine months ended June 30, 2020 was $269,437, and $819,498, respectively. Unsecured notes On March 7, 2019, the Company entered into a forbearance and exchange agreement with Iliad Research and Trading, L.P., a Utah limited partnership (the “Lender”). Concurrently with the execution of this agreement, the Lender purchased two stockholder notes issued by the Company previously in the original principal amount of $1,000,000 with an aggregate outstanding balance as of March 7, 2019 of $1,947,133, including accrued interest. The stockholder notes were accruing interest at the rate of 2.5% per month. The Lender agreed to refrain and forbear from bringing any action to collect under the stockholder notes until March 7, 2020 and to reduce the interest rates currently in effect to 12.0% per annum simple interest during such forbearance period. The Company also agreed to, at Lender’s election, repay or exchange the stockholder notes (or portions thereof) for shares of the Company's common stock at an exchange rate of $13.44 per share or, beginning September 2019, at 95% of the average of the two lowest closing bid prices in the prior twenty trading days, as applicable. During the three months ended December 31, 2019, the remaining unsecured notes with an aggregate carrying amount of $977,966 and accrued interest of $570,460 were exchanged for 1,475,258 shares of the Company’s common stock at an average exchange price of $1.10. As of December 31, 2019, these unsecured notes were no longer outstanding. During the nine months ended June 30, 2020, the Company recognized $12,997 of interest expense related to the unsecured notes. No interest expense related to the unsecured notes was recognized during the three months ended June 30, 2020. Stockholder notes ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 September 30, 2020 Restricted stock repurchase notes ​ $ — ​ $ 800,000 Common stock repurchase note ​ ​ — ​ ​ 2,812,500 ​ ​ ​ — ​ ​ 3,612,500 Less: current portion ​ ​ — ​ ​ (3,612,500) ​ ​ $ — ​ $ — ​ The Company previously repurchased shares of its restricted stock in exchange for notes in the amount of $800,000 that did not bear interest and were due on demand. These notes were paid in full in November 2020. ​ The Company had a $2,812,500 note payable related to the previous repurchase of common stock that did not bear interest and was due on demand. This note was paid in full in November 2020.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Jun. 30, 2021
Commitments and Contingencies.
Commitments and Contingencies	9. Commitments and Contingencies ​ Litigation ​ On July 20, 2020, Laboratorios Liomont S.A. de C.V. (“Liomont”), filed a complaint against the Company in the U.S. District Court of the Southern District of New York alleging certain breach of contract claims under the June 25, 2014 strategic development, license and supply agreement relating to the biosimilar development program for ONS-3010 and ONS-1045 claiming $3,000,000 in damages. On March 30, 2021, the Company entered into a confidential settlement agreement with Liomont, and the complaint was dismissed on April 11, 2021. The Company agreed to make an initial settlement payment of $625,000 that was paid in April 2021; and an additional payment of $750,000, which is contingent upon the occurrence of certain future events. Leases ​ Corporate office and warehouse leases ​ In March 2021, the Company assigned its Monmouth Junction, New Jersey corporate office lease to a third party and as of June 30, 2021, did not have remaining future obligations. Upon assignment, the Company recognized a gain of $10,250. In March 2021, the Company entered into a new three-year term corporate office lease in Iselin, New Jersey which commenced on April 23, 2021. The future minimum lease payments for the new lease total $135,535. On May 6, 2020, the Company terminated its lease agreement for approximately 66,000 square feet of office, manufacturing and laboratory space located in Cranbury, New Jersey, which previously served as its headquarters, and relocated its corporate office to Monmouth Junction, New Jersey, a site previously used as a warehouse location. The Company’s Monmouth Junction, New Jersey lease was due to mature in September 2021. In consideration for the termination of the Cranbury lease, the Company agreed to make payments to the landlord totaling $981,987, payable in eight A rollforward of the charges incurred to general and administrative expense for the nine months ended June 30, 2021 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance ​ Expensed / Accrued ​ Cash ​ Non-cash ​ Balance ​ October 1, 2020 Expense Payments Adjustments June 30, 2021 Lease termination payments ​ $ 356,987 ​ $ — ​ $ (356,987) ​ $ — ​ $ — ​ Equipment leases ​ The Company has equipment leases, with terms between 12 and 36 months, recorded as finance leases. The equipment leases bear interest between 4.0% and 13.0%. ​ Certain lease agreements contain provisions for future rent increases. Payments due under the lease contracts include minimum payments that the Company is obligated to make under the non-cancelable initial terms of the leases as the renewal terms are at the Company’s option. Lease expense is recorded as research and development or general and administrative based on the use of the leased asset. ​ The components of lease cost for the three and nine months ended June 30, 2021 and 2020 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended June 30, ​ Nine months ended June 30, ​ 2021 2020 2021 2020 Finance lease cost: ​ ​ ​ ​ Amortization of right-of-use assets ​ $ — ​ $ 32,967 ​ $ — ​ $ 182,967 Interest on lease liabilities ​ 1,210 ​ 165,191 ​ 3,997 ​ 903,278 Total finance lease cost ​ 1,210 ​ 198,158 ​ 3,997 ​ 1,086,245 Operating lease cost ​ 8,413 ​ 43,625 ​ 95,663 ​ 130,875 Total lease cost ​ $ 9,623 ​ $ 241,783 ​ $ 99,660 ​ $ 1,217,120 ​ Amounts reported in the consolidated balance sheets for leases where the Company is the lessee are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 September 30, 2020 Operating leases: ​ ​ ​ Right-of-use asset ​ $ 121,197 ​ $ 166,986 Operating lease liabilities ​ 79,923 ​ 187,486 Finance leases: ​ ​ Right-of-use asset ​ $ — ​ $ — Financing lease liabilities ​ 49,162 ​ 72,260 Weighted-average remaining lease term (years): ​ ​ Operating leases ​ ​ 2.8 ​ ​ 1.0 Finance leases ​ 1.9 ​ 2.4 Weighted-average discount rate: ​ ​ Operating leases ​ ​ 7.5% ​ ​ 9.0% Finance leases ​ 9.2% ​ 8.5% ​ Other information related to leases for the nine months ended June 30, 2021 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine months ended June 30, ​ 2021 2020 Cash paid for amounts included in the measurement of lease obligations: ​ ​ ​ Operating cash flows from finance leases ​ $ 3,997 ​ $ 903,278 Operating cash flows from operating leases ​ 147,187 ​ 140,625 Financing cash flows from finance leases ​ 23,098 ​ 196,959 Right-of-use assets obtained in exchange for lease obligations: ​ ​ Operating leases ​ $ 128,473 ​ $ — Finance leases ​ — ​ — ​ Future minimum lease payments under non-cancelable leases as of June 30, 2021 are as follows for the years ending September 30: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ Finance leases 2021 (remaining three months) ​ $ 11,522 ​ $ 7,775 2022 ​ 46,652 ​ 29,605 2023 ​ 27,675 ​ 13,149 2024 ​ — ​ 4,383 Total undiscounted lease payments ​ $ 85,849 ​ $ 54,912 Less: Imputed interest ​ 5,926 ​ 5,750 Total lease obligations ​ $ 79,923 ​ $ 49,162 ​ Office and laboratory lease termination obligation ​ In August 2018, the Company entered into a lease termination agreement effective September 1, 2018, to terminate the lease for unutilized office and laboratory space in Cranbury, New Jersey. In consideration for the termination of the lease, the Company agreed to make payments to the landlord totaling up to $5.8 million, which included (i) $287,615 upon execution of the termination agreement, (ii) $50,000 per month for up to 30 months, commencing September 1, 2018, and (iii) a $4.0 million payment, in any event, on or before February 1, 2021. The Company and landlord agreed that the $174,250 security deposit will be used to pay the 7th, 8th, 9th and a portion of the 10th monthly payments. In November 2020, the Company fully settled the remaining lease termination payments for a one-time cash payment of $3,250,000 and $190,336 security deposit from the terminated Cranbury, New Jersey corporate office lease. Upon settlement, the Company recognized a gain of $542,090 in general and administrative expenses which represented the difference between the carrying value of the liability at the time of settlement and the settlement amounts. ​ A roll forward of the charges incurred to general and administrative expense for the nine months ended June 30, 2021 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance ​ Expensed / Accrued ​ Cash ​ ​ Non-cash ​ Balance ​ October 1, 2020 Expense Payments ​ ​ Adjustments ​ June 30, 2021 Lease termination payments ​ $ 3,971,111 ​ $ 111,315 ​ $ (3,540,336) ​ $ (542,090) ​ $ — ​

Common Stock, Convertible Prefe

Common Stock, Convertible Preferred Stock and Stockholders Equity (Deficit)	9 Months Ended
	Jun. 30, 2021
Common Stock, Convertible Preferred Stock and Stockholders Equity (Deficit)
Common Stock, Convertible Preferred Stock and Stockholders' Equity (Deficit)	10. Common Stock, Convertible Preferred Stock and Stockholders’ Equity (Deficit) Common stock In February 2021, the Company issued in an underwritten public offering, including partial exercise of the underwriters’ overallotment option, an aggregate of 38,593,767 shares of common stock at a purchase price per share of $1.00 for $35.5 million in net proceeds after payment of underwriter discounts and commissions and other underwriter offering costs. GMS Ventures and Investments (“GMS Ventures”), an affiliate of BioLexis Pte. Ltd. (“BioLexis”), the Company’s largest stockholder and strategic partner, purchased an aggregate of 8,360,000 shares of common stock in the public offering at the public offering price per share. In a separate concurrent private placement, the Company issued 3,000,000 shares of common stock to Syntone Ventures at a purchase price of $1.00 per share for aggregate gross proceeds of $3.0 million. Following partial exercise of the underwriters’ overallotment option subsequent to the initial closing, and pursuant to the Investor Rights Agreement dated as of September 11, 2017 and as amended, by and among the Company, BioLexis and GMS Ventures, the Company sold an additional 1,013,627 shares of common stock to GMS Ventures in a private placement for aggregate gross proceeds to the Company of $1.0 million at the public offering price per share of $1.00. In connection with the underwritten public offering (including the partial exercise of the overallotment option) the Company issued the underwriter warrants to purchase up to an aggregate of 2,116,364 shares of common stock at an exercise price of $1.25 per share, which warrants have a 5-year term. On March 24, 2021, following receipt of stockholder approval at the Company’s 2021 annual meeting of stockholders, the number of authorized shares of common stock was increased from 200,000,000 shares to 325,000,000 shares. In February 2020, the Company issued, in a registered direct offering, an aggregate of 7,598,426 shares of common stock and, in a concurrent private placement to the same investors, warrants to purchase up to an aggregate of 3,799,213 shares of common stock at a combined purchase price per share and accompanying warrant of $1.016 for approximately $6.7 million in net proceeds after payment of placement agent fees and other offering costs. In a separate concurrent private placement, the Company issued 2,460,630 shares of common stock and warrants to purchase up to an aggregate of 1,230,315 shares of common stock to GMS Ventures, at a combined purchase price per share and accompanying warrant of $1.016 for $2.5 million. The warrants issued were exercisable immediately at an exercise price of $0.9535 per share and will expire four years from the issuance date. In connection with the registered direct offering and concurrent private placement of warrants to those investors, the Company issued placement agent warrants to purchase up to an aggregate of 531,890 shares of common stock, on substantially the same terms as the concurrent private placement warrants, at an exercise price of $1.27 per share and a 5-year term. Effective March 19, 2020, following approval of the Company’s stockholders, the Company issued an aggregate of 7,244,739 shares of its common stock to the four former principals (who include two of its named executive officers, Messrs. Dagnon and Evanson) of MTTR, LLC (“MTTR”) pursuant to their respective consulting agreements that were entered into on January 27, 2020 concurrent with the termination agreement and mutual release with MTTR to terminate the strategic partnership agreement. Refer to Note 11 for the accounting of the restricted stock issued and Note 12 for further details on the terminated MTTR strategic partnership agreement. In June 2020, the Company issued, in a private placement, an aggregate of 16,000,000 shares of common stock to Syntone, pursuant to a stock purchase agreement entered into on May 22, 2020, at a purchase price of $1.00 per share, for aggregate gross proceeds to the Company of $16.0 million. In June 2020, the Company issued, in a registered direct offering, an aggregate of 8,407,411 shares of common stock at a purchase price of $1.215 per share, for aggregate gross proceeds to the Company of approximately $10.2 million. In connection with the registered direct offering, the Company issued placement agent warrants to purchase up to an aggregate of 588,519 shares of common stock, at an exercise price of $1.51875 per share and a 5-year During the nine months ended June 30, 2020, the Company issued 109 shares of common stock upon the vesting of RSUs. H.C. Wainwright & Co. At-the-Market Offering Agreement On March 26, 2021, the Company entered into an At-the-Market Offering Agreement (the “Agreement”) with H.C. Wainwright & Co., as sales agent (“Wainwright” or the “Agent”), under which the Company may issue and sell shares of its common stock from time to time through Wainwright as sales agent. The Company filed a prospectus supplement, dated March 26, 2021, with the Securities and Exchange Commission pursuant to which the Company may offer and sell shares of common stock having an aggregate offering price of up to up to $40.0 million from time to time through Wainwright. The Company incurred financing costs of $197,654 which were capitalized and are being reclassified to additional paid in capital on a pro rata basis when the Company sells common stock under the ATM Offering. As of June 30, 2021, $181,763 of such deferred costs are included in other assets on the consolidated balance sheets. Under the Agreement, the Company pays Wainwright a commission equal to 3.0% of the aggregate gross proceeds of any sales of common stock under the Agreement. The offering of common stock pursuant to the Agreement will terminate upon the earlier of (i) the sale of all common stock subject to the Agreement or (ii) termination of the Agreement in accordance with its terms. During the three months ended June 30, 2021, the Company sold 1,207,519 shares of common stock under the ATM Offering and generated $3.2 million in gross proceeds. The Company paid fees to the sales agent of $0.1 million. Refer to Note 13 for shares of common stock sold under the ATM Offering after June 30, 3021. Series A-1 convertible preferred stock A total of 200,000 shares of Series A-1 Convertible Preferred Stock (the “Series A-1”) were authorized for issuance under the Certificate of Designation of Series A-1 Convertible Preferred Stock of the Company (the “Certificate of Designation”). The shares of Series A-1 had a stated value of $100.00 per share, and ranked senior to all junior securities (as defined in the Certificate of Designation). On March 23, 2020, the Company issued 29,358,621 shares of its common stock upon conversion of all 68,112 shares of Series A-1 outstanding by BioLexis, pursuant to an agreement entered on January 27, 2020 with BioLexis, whereby the effective conversion rate of the Series A-1 was increased from the $18.89797 per share to $431.03447263 per share, (or an effective conversion rate of $0.232 per share) following stockholder approval of the amended terms on March 19, 2020. The amendment to the Series A-1 was deemed an extinguishment for accounting purposes. The excess fair value of common stock received over the net carrying value of the Series A-1 was $10,328,118 and reflected as a deemed dividend in the consolidated statements of operations for purposes of presenting net loss attributable to common stockholders when calculating basic and diluted loss per share. As of June 30, 2021 and September 30, 2020, there were no shares of Series A-1 outstanding. The Series A-1 accrued dividends at a rate of 10% per annum, compounded quarterly, payable quarterly at the Company’s option in cash or in kind in additional shares of Series A-1. During the nine months ended June 30, 2020, the Company issued 1,661 shares of Series A-1 to settle the related dividends that were due on a quarterly basis. Common stock warrants As of June 30, 2021, shares of common stock issuable upon the exercise of outstanding warrants were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Shares of ​ ​ ​ ​ ​ common stock ​ ​ ​ ​ ​ issuable upon ​ ​ ​ ​ ​ exercise of ​ Exercise Price ​ Expiration Date warrants Per Share ​ February 18, 2022 ​ 416,666 ​ $ 12.00 ​ December 22, 2024 (i) 277,128 ​ $ 12.00 ​ April 13, 2025 (i) 145,686 ​ $ 12.00 ​ May 31, 2025 (i) 62,437 ​ $ 12.00 ​ February 24, 2025 ​ 172,864 ​ $ 1.27 ​ February 26, 2024 ​ 1,747,047 ​ $ 0.9535 ​ June 22, 2025 ​ 191,268 ​ $ 1.5188 ​ January 28, 2026 ​ 2,116,364 ​ $ 1.2500 ​ ​ ​ 5,129,460 ​ ​ ​ ​ ​ (i) The warrants were issued in connection with the convertible senior secured notes (see Note 8) and are classified as liabilities on the accompanying consolidated balance sheets as the warrants include cash settlement features at the option of the holders under certain circumstances. Refer to Note 4 for fair value measurements disclosures. On December 23, 2019, the Company amended the terms of its outstanding 15-month warrants and five-year The estimated change in fair value of warrants amended during the nine months ended June 30, 2020 was $3,140,009, and reflected as a deemed dividend in the consolidated statements of operations for purposes of presenting net loss attributable to common stockholders when calculating basic and diluted loss per share. During the nine months ended June 30, 2021, warrants to purchase an aggregate of 3,641,507 shares of common stock with a weighted averaged exercise price of $0.9847 were exercised for aggregate gross proceeds to the Company of $3,585,809. In addition, warrants to purchase an aggregate of 397,251 shares of common stock with a weighted averaged exercise price of $1.51875 were exercised on a cashless basis. During the nine months ended June 30, 2020, warrants to purchase an aggregate of 15,085,240 shares of common stock with a weighted averaged exercise price of $0.232 were exercised for an aggregate 13,003,414 shares of the Company's common stock; and warrants to purchase an aggregate of 80,797 shares of common stock with a weighted averaged exercise price of $0.08 expired. In aggregate, 10,157,050 of the exercised warrants were April 2019 Warrants, described above, exercised pursuant to the net exercise provisions therein, as amended.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Jun. 30, 2021
Stock-Based Compensation
Stock-Based Compensation	11. Stock-Based Compensation 2011 Equity Incentive Plan The Company’s 2011 Equity Compensation Plan (the “2011 Plan”) provided for the Company to sell or issue restricted common stock, RSUs, performance-based awards (“PSUs”), cash-based awards or to grant stock options for the purchase of common stock to officers, employees, consultants and directors of the Company. The 2011 Plan was administered by the board of directors or, at the discretion of the board of directors, by a committee of the board. The number of shares of common stock reserved for issuance under the 2011 Plan is 106,490. As of June 30, 2021, PSUs representing 2,470 shares of the Company’s common stock were outstanding under the 2011 Plan. Effective with the December 2015 adoption of the 2015 Equity Incentive Plan, (the “2015 Plan”), no future awards under the 2011 Plan will be granted. 2015 Equity Incentive Plan In December 2015, the Company adopted the 2015 Plan. The 2015 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, RSU awards, performance stock awards and other forms of equity compensation to Company employees, directors and consultants. The aggregate number of shares of common stock authorized for issuance pursuant to the Company’s 2015 Plan is 27,838,019. As of June 30, 2021, 15,558,352 shares remained available for grant under the 2015 Plan. Stock options and RSUs are granted under the Company’s 2015 Plan and generally vest over a period of one The Company recorded stock-based compensation expense in the following expense categories of its statements of operations for the three and nine months ended June 30, 2021 and 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended June 30, ​ Nine months ended June 30, ​ ​ 2021 2020 2021 2020 Research and development ​ $ 239,231 ​ $ 915,974 ​ $ 707,442 ​ $ 1,064,912 General and administrative ​ ​ 959,153 ​ ​ 442,746 ​ ​ 2,775,330 ​ ​ 957,824 ​ ​ $ 1,198,384 ​ $ 1,358,720 ​ $ 3,482,772 ​ $ 2,022,736 ​ Stock options As of June 30, 2021, options to purchase common stock of the Company outstanding under the 2015 Plan were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ ​ ​ ​ Weighted ​ Remaining ​ ​ ​ ​ ​ Number of ​ Average ​ Contractual ​ Aggregate ​ Shares Exercise Price Term (Years) Intrinsic Value Balance at October 1, 2020 ​ 3,762,143 ​ $ 2.01 ​ ​ ​ ​ ​ Granted ​ 8,461,645 ​ ​ 0.76 ​ ​ ​ ​ ​ Exercised ​ — ​ ​ — ​ ​ ​ ​ ​ Forfeited or expired ​ (113,773) ​ ​ 0.77 ​ ​ ​ ​ ​ Balance at June 30, 2021 ​ 12,110,015 ​ ​ 1.15 ​ 9.0 ​ $ 18,041,745 Vested and exercisable ​ 2,098,726 ​ ​ 1.77 ​ 8.6 ​ $ 2,673,290 Vested and expected to vest at June 30, 2021 ​ 12,110,015 ​ $ 1.15 ​ 9.0 ​ ​ ​ ​ The aggregate intrinsic value represents the total amount by which the fair value of the common stock subject to options exceeds the exercise price of the related options. The weighted average grant date fair value of the options awarded to employees for the nine months ended June 30, 2021 and 2020 was $0.57 and $0.71 per option, respectively. The fair value of the options was estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions: ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine months ended June 30, ​ ​ ​ 2021 2020 ​ Risk-free interest rate 0.40 % 1.08 % Expected term (years) ​ 6.01 ​ 5.73 ​ Expected volatility ​ 95.4 % 89.3 % Expected dividend yield ​ — ​ — ​ ​ As of June 30, 2021, there was $4,988,744 of unrecognized compensation expense that is expected to be recognized over a weighted-average period of 2.64 years. ​ Performance-based stock units The Company has issued PSUs, which generally have a ten-year term from the date of grant. Upon exercise, the PSU holder receives common stock or cash at the Company’s discretion. The following table summarizes the activity related to PSUs during the nine months ended June 30, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Average ​ ​ Number ​ Base ​ Remaining ​ ​ of ​ Price ​ Contractual ​ PSUs Per PSU Term (Years) Balance at October 1, 2020 ​ 2,470 ​ $ 49.97 ​ ​ Forfeitures ​ — ​ ​ — ​ ​ Balance at June 30, 2021 ​ 2,470 ​ ​ 49.97 ​ 3.5 Vested and exercisable at June 30, 2021 ​ 2,470 ​ ​ 49.97 ​ 3.5 Vested and expected to vest at June 30, 2021 ​ 2,470 ​ $ 49.97 ​ 3.5 ​ Restricted stock In connection with the consulting agreements entered into by the Company and four former principals of MTTR, in March 2020, the Company issued an aggregate of 7,244,739 shares of its common stock. Refer to Note 12 for further details on the consulting agreements and terminated strategic partnership agreement. These shares may not be sold until the earlier of  (i) six months following FDA approval of ONS-5010, (ii) the date the Company publicly announces not to pursue development of ONS-5010, (iii) a change in control or (iv) January 2025. In addition, the Company has the right to repurchase the shares for $0.01 per share if the consultant terminates his agreement other than for good reason or the Company terminates the agreement for cause. The repurchase right lapses, in tiered percentages, based upon the completion of enrollment of the Company’s NORSE TWO clinical trial of ONS-5010 by certain dates. The repurchase right may also lapse as to 50% or 100% of the shares if the Company enters into certain agreements pertaining to ONS-5010 that meet certain value thresholds or the Company’s share price meets certain predefined targets. The repurchase right also lapses as to 100% of the shares upon the earliest to occur of (i) filing of the BLA for ONS-5010, (ii) termination of the agreement by the consultant for good reason or by the Company other than for cause, (iii) in the event of disability, or (iv) upon a change in control. As of June 30, 2021, 1,811,184 shares of common stock were vested and not subject to repurchase rights. ​ The grant date fair value of the restricted shares was $0.54 per share and equal to the closing stock price of the Company’s common stock at the time of grant. Compensation expense is recognized over the shorter of the explicit service period or derived service period, which was determined to be 4.8 years at the time of grant. Compensation expense may be accelerated when certain performance conditions become probable and the corresponding purchase right has lapsed. During the three and nine months ended June 30, 2021, the Company recognized compensation expense related to the restricted stock of $151,764 and $455,293, respectively. During the three and nine months ended June 30, 2020, the Company recognized compensation expense related to the restricted stock of $1,070,404 and $1,149,387, respectively. As of June 30, 2021, there was $2,155,713 of unrecognized compensation expense related to the restricted stock.

Related-Party Transactions

Related-Party Transactions	9 Months Ended
	Jun. 30, 2021
Related-Party Transactions
Related-Party Transactions	12. Related-Party Transactions MTTR - strategic partnership agreement (ONS-5010) In February 2018, the Company entered into a strategic partnership agreement with MTTR to advise on regulatory, clinical and commercial strategy and assist in obtaining approval of ONS-5010, the Company's bevacizumab therapeutic product candidate for ophthalmic indications. In November 2018, the board of directors of the Company appointed Mr. Terry Dagnon as Chief Operating Officer, and Mr. Jeff Evanson as Chief Commercial Officer. Both Mr. Dagnon and Mr. Evanson initially provided services to the Company pursuant to the February 2018 strategic partnership agreement with MTTR, as amended. Mr. Dagnon and Mr. Evanson were both principals in MTTR. The Company did not pay Mr. Dagnon or Mr. Evanson any direct compensation as consultants or as employees during the three months ended December 31, 2019 nor during the period from October 1, 2019 through March 19, 2020. Both Mr. Dagnon and Mr. Evanson were compensated directly by MTTR for services provided to the Company as the Company's Chief Operating Officer and Chief Commercial Officer, respectively, pursuant to the strategic partnership agreement until such agreement, as amended, was terminated effective March 19, 2020. The Company began compensating Mr. Dagnon and Mr. Evanson directly as consultants effective March 19, 2020 pursuant to their respective consulting agreements with the Company, which became effective March 19, 2020 following stockholder approval of the share issuances contemplated therein. Mr. Dagnon and Mr. Evanson have also agreed to provide consulting services to an affiliate of BioLexis pursuant to a separate arrangement. ​ On January 27, 2020, the Company entered into a termination agreement and mutual release with MTTR to terminate the strategic partnership agreement. Pursuant to the agreement, the Company agreed (x) to issue to the four principals of MTTR (who include two of its named executive officers, Messrs. Dagnon and Evanson), an aggregate of 7,244,739 shares of its common stock, subject to stockholder approval, (y) to enter into consulting agreements with each of the four principals setting forth the terms of his respective compensation arrangement, and (z) to pay MTTR a one-time settlement fee of $110,000, upon effectiveness of the agreement. ​ Concurrently, the Company also entered into consulting agreements directly with each of the four principals of MTTR setting forth the terms of his respective compensation arrangement, as well as providing for certain transfer restrictions and repurchase rights applicable to the shares of common stock to be issued pursuant hereto. The termination agreement, and the consulting agreements, became effective upon stockholder approval of the share issuance on March 19, 2020. Refer to Note 11 for the accounting of the restricted stock issued and compensation expense recognized. ​ During the three months ended June 30, 2021 and 2020, MTTR and its four principals under the strategic partnership agreement and the subsequent individual consulting agreements earned an aggregate $271,583 and $242,603 , respectively; and $812,808 and $1,023,374 during the nine months ended June 30, 2021 and 2020, respectively, which includes monthly consulting fees and expense reimbursement, but excludes stock-based compensation related to restricted stock (Note 11). As of June 30, 2021, and September 30, 2020 an aggregate $90,476 and $89,762 , respectively, was due to the former MTTR principals as consultants, which is included in accounts payable in the accompanying consolidated balance sheets.

Subsequent Events

Subsequent Events	9 Months Ended
	Jun. 30, 2021
Subsequent Events
Subsequent Events	13. Subsequent Events Sales of common stock pursuant to ATM Offering In July 2021, the Company sold 527,216 shares of common stock under its ATM Offering. The Company generated $1.3 million in net proceeds from the ATM Offering program after payment of fees to the sales agent of $43,000. Stock options grants In July 2021, the Company granted 5,000,000 stock options with an average exercise price of $2.42 to the Company’s newly appointed Chief Executive Officer. ​

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Jun. 30, 2021
Basis of Presentation and Summary of Significant Accounting Policies
Basis of presentation	Basis of presentation The accompanying unaudited interim consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). In the opinion of management, the accompanying unaudited interim consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s financial position as of June 30, 2021 and its results of operations for the three and nine months ended June 30, 2021 and 2020, cash flows for the nine months ended June 30, 2021 and 2020, and convertible preferred stock and stockholders’ equity (deficit) for the three and nine months ended June 30, 2021 and 2020. Operating results for the three and nine months ended June 30, 2021 are not necessarily indicative of the results that may be expected for the full year ending September 30, 2021. The unaudited interim consolidated financial statements, presented herein, do not contain the required disclosures under GAAP for annual consolidated financial statements. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended September 30, 2020 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on December 23, 2020 and amended on January 28, 2021.
Use of estimates	Use of estimates The preparation of the unaudited interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the unaudited interim consolidated financial statements, including as a result of the ongoing COVID-19 pandemic, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary.
Equity method investment	Equity method investment The Company accounts for equity investments where it owns a non-controlling interest, but has the ability to exercise significant influence, under the equity method of accounting. Under the equity method of accounting, the original cost of the investment is adjusted for the Company’s share of equity in the earnings or loss of the equity investee and reduced by dividends and distributions of capital received, unless the fair value option is elected, in which case the investment balance is marked to fair value each reporting period and the impact of changes in fair value of the equity investment are reported in earnings. The Company has not elected the fair value option. The Company assesses its investment for other-than-temporary impairment when events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable and recognize an impairment loss to adjust the investment to its then-current fair value.
Net loss per share	Net loss per share Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. For purposes of calculating diluted loss per common share, the denominator includes both the weighted average common shares outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and non-vested restricted stock unit (“RSU”) awards using the treasury stock method. For all periods presented, there is no difference in the number of shares used to compute basic and diluted shares due to the Company’s loss. The following table sets forth the computation of basic earnings per share and diluted earnings per share: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended June 30, ​ Nine months ended June 30, ​ 2021 2020 2021 2020 Net loss attributable to common stockholders ​ $ (12,196,547) ​ $ (3,014,867) ​ $ (39,758,982) ​ $ (38,952,142) Common stock outstanding (weighted average) ​ ​ 168,420,675 ​ ​ 90,757,825 ​ ​ 146,860,652 ​ ​ 56,089,036 Basic and diluted net loss per share ​ $ (0.07) ​ $ (0.03) ​ $ (0.27) ​ $ (0.69) ​ The following potentially dilutive securities (in common stock equivalents) have been excluded from the computation of diluted weighted-average shares outstanding as of June 30, 2021 and 2020, as they would be antidilutive: ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, ​ 2021 2020 Performance-based stock units ​ 2,470 ​ 2,470 Stock options ​ 12,110,015 ​ 2,238,470 Common stock warrants ​ 5,129,460 ​ 7,051,857 ​
Recently issued accounting pronouncements	Recently issued accounting pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) Disclosure Framework — Changes to the Disclosure Requirements for Fair Value Measurement ​ In January 2020, FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Jun. 30, 2021
Basis of Presentation and Summary of Significant Accounting Policies
Schedule of computation of basic earnings per share and diluted earnings per share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended June 30, ​ Nine months ended June 30, ​ 2021 2020 2021 2020 Net loss attributable to common stockholders ​ $ (12,196,547) ​ $ (3,014,867) ​ $ (39,758,982) ​ $ (38,952,142) Common stock outstanding (weighted average) ​ ​ 168,420,675 ​ ​ 90,757,825 ​ ​ 146,860,652 ​ ​ 56,089,036 Basic and diluted net loss per share ​ $ (0.07) ​ $ (0.03) ​ $ (0.27) ​ $ (0.69)
Schedule of dilutive securities excluded from the computation weighted-average shares	​ ​ ​ ​ ​ ​ ​ ​ As of June 30, ​ 2021 2020 Performance-based stock units ​ 2,470 ​ 2,470 Stock options ​ 12,110,015 ​ 2,238,470 Common stock warrants ​ 5,129,460 ​ 7,051,857 ​

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Jun. 30, 2021
Fair Value Measurements
Schedule of assets and liabilities measured at fair value on a recurring basis	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 ​ (Level 1) (Level 2) (Level 3) Liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrant liability ​ $ — ​ $ — ​ $ 434,248 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2020 ​ ​ (Level 1) (Level 2) (Level 3) Liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrant liability ​ $ — ​ $ — ​ $ 70,772
Schedule of changes in the fair value of Level 3 valuation for the warrant liability	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrants Balance at October 1, 2020 ​ $ 70,772 Change in fair value ​ ​ 363,476 Balance at June 30, 2021 ​ $ 434,248 ​
Schedule of fair value of the warrant liability	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 September 30, 2020 Risk-free interest rate ​ ​ 0.59 % ​ ​ 0.24 % Remaining contractual term of warrant ​ ​ 3.6 years ​ ​ 4.4 years Expected volatility ​ ​ 98.3 % ​ ​ 94.7 % Annual dividend yield ​ ​ — % ​ ​ — % Fair value of common stock ​ $ 2.49 per ​ $ 0.72 per

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	9 Months Ended
	Jun. 30, 2021
Property and Equipment, Net
Schedule of property and equipment	​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 September 30, 2020 Laboratory equipment ​ $ 1,067,351 ​ $ 1,067,351 Less: accumulated depreciation and amortization ​ ​ (862,820) ​ ​ (740,102) ​ ​ $ 204,531 ​ $ 327,249

Other Assets (Tables)

Other Assets (Tables)	9 Months Ended
	Jun. 30, 2021
Other Assets.
Schedule of other assets	​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 September 30, 2020 Investment in PRC joint venture ​ $ — ​ $ 900,000 Other assets ​ ​ 194,355 ​ ​ 394,448 ​ ​ $ 194,355 ​ $ 1,294,448

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Jun. 30, 2021
Accrued Expenses
Schedule of accrued expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 September 30, 2020 Compensation ​ $ 452,278 ​ $ 579,618 Severance and related costs ​ ​ — ​ ​ 9,521 Research and development ​ ​ 2,837,663 ​ ​ 2,890,333 Interest payable ​ ​ 10,454 ​ ​ 3,691 Professional fees ​ ​ 43,302 ​ ​ 132,085 Lease termination obligation ​ ​ — ​ ​ 3,971,111 Other accrued expenses ​ ​ 148,247 ​ ​ 170,951 ​ ​ $ 3,491,944 ​ $ 7,757,310

Debt (Tables)

Debt (Tables)	9 Months Ended
	Jun. 30, 2021
Debt
Schedule of debt	​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 September 30, 2020 Unsecured promissory note ​ $ 10,734,986 ​ $ — Paycheck Protection Program term loan ​ ​ 904,200 ​ ​ 904,200 Equipment loans ​ ​ 13,042 ​ ​ 50,285 Total debt ​ ​ 11,652,228 ​ ​ 954,485 Less: unamortized loan costs ​ ​ (102,803) ​ ​ — Total debt, net of unamortized loan costs ​ ​ 11,549,425 ​ ​ 954,485 Less: current portion ​ ​ (11,549,425) ​ ​ (50,285) Long-term debt ​ $ — ​ $ 904,200
Schedule of stockholder notes	​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 September 30, 2020 Restricted stock repurchase notes ​ $ — ​ $ 800,000 Common stock repurchase note ​ ​ — ​ ​ 2,812,500 ​ ​ ​ — ​ ​ 3,612,500 Less: current portion ​ ​ — ​ ​ (3,612,500) ​ ​ $ — ​ $ —

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Jun. 30, 2021
Long-term Purchase Commitment [Line Items]
Schedule of lease information	​ The components of lease cost for the three and nine months ended June 30, 2021 and 2020 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended June 30, ​ Nine months ended June 30, ​ 2021 2020 2021 2020 Finance lease cost: ​ ​ ​ ​ Amortization of right-of-use assets ​ $ — ​ $ 32,967 ​ $ — ​ $ 182,967 Interest on lease liabilities ​ 1,210 ​ 165,191 ​ 3,997 ​ 903,278 Total finance lease cost ​ 1,210 ​ 198,158 ​ 3,997 ​ 1,086,245 Operating lease cost ​ 8,413 ​ 43,625 ​ 95,663 ​ 130,875 Total lease cost ​ $ 9,623 ​ $ 241,783 ​ $ 99,660 ​ $ 1,217,120 ​ Amounts reported in the consolidated balance sheets for leases where the Company is the lessee are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 September 30, 2020 Operating leases: ​ ​ ​ Right-of-use asset ​ $ 121,197 ​ $ 166,986 Operating lease liabilities ​ 79,923 ​ 187,486 Finance leases: ​ ​ Right-of-use asset ​ $ — ​ $ — Financing lease liabilities ​ 49,162 ​ 72,260 Weighted-average remaining lease term (years): ​ ​ Operating leases ​ ​ 2.8 ​ ​ 1.0 Finance leases ​ 1.9 ​ 2.4 Weighted-average discount rate: ​ ​ Operating leases ​ ​ 7.5% ​ ​ 9.0% Finance leases ​ 9.2% ​ 8.5% ​ Other information related to leases for the nine months ended June 30, 2021 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine months ended June 30, ​ 2021 2020 Cash paid for amounts included in the measurement of lease obligations: ​ ​ ​ Operating cash flows from finance leases ​ $ 3,997 ​ $ 903,278 Operating cash flows from operating leases ​ 147,187 ​ 140,625 Financing cash flows from finance leases ​ 23,098 ​ 196,959 Right-of-use assets obtained in exchange for lease obligations: ​ ​ Operating leases ​ $ 128,473 ​ $ — Finance leases ​ — ​ —
Schedule of operating lease future minimum payments	Future minimum lease payments under non-cancelable leases as of June 30, 2021 are as follows for the years ending September 30: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ Finance leases 2021 (remaining three months) ​ $ 11,522 ​ $ 7,775 2022 ​ 46,652 ​ 29,605 2023 ​ 27,675 ​ 13,149 2024 ​ — ​ 4,383 Total undiscounted lease payments ​ $ 85,849 ​ $ 54,912 Less: Imputed interest ​ 5,926 ​ 5,750 Total lease obligations ​ $ 79,923 ​ $ 49,162
Schedule of finance lease future minimum payments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ Finance leases 2021 (remaining three months) ​ $ 11,522 ​ $ 7,775 2022 ​ 46,652 ​ 29,605 2023 ​ 27,675 ​ 13,149 2024 ​ — ​ 4,383 Total undiscounted lease payments ​ $ 85,849 ​ $ 54,912 Less: Imputed interest ​ 5,926 ​ 5,750 Total lease obligations ​ $ 79,923 ​ $ 49,162
Cranbury NJ, May 2020 lease termination
Long-term Purchase Commitment [Line Items]
Schedule of future termination payment derecognized	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance ​ Expensed / Accrued ​ Cash ​ Non-cash ​ Balance ​ October 1, 2020 Expense Payments Adjustments June 30, 2021 Lease termination payments ​ $ 356,987 ​ $ — ​ $ (356,987) ​ $ — ​ $ —
Cranbury NJ, August 2018 lease termination
Long-term Purchase Commitment [Line Items]
Schedule of future termination payment derecognized	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance ​ Expensed / Accrued ​ Cash ​ ​ Non-cash ​ Balance ​ October 1, 2020 Expense Payments ​ ​ Adjustments ​ June 30, 2021 Lease termination payments ​ $ 3,971,111 ​ $ 111,315 ​ $ (3,540,336) ​ $ (542,090) ​ $ —

Common Stock, Convertible Pre_2

Common Stock, Convertible Preferred Stock and Stockholders Equity (Deficit) (Tables)	9 Months Ended
	Jun. 30, 2021
Common Stock, Convertible Preferred Stock and Stockholders Equity (Deficit)
Schedule of warrants outstanding	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Shares of ​ ​ ​ ​ ​ common stock ​ ​ ​ ​ ​ issuable upon ​ ​ ​ ​ ​ exercise of ​ Exercise Price ​ Expiration Date warrants Per Share ​ February 18, 2022 ​ 416,666 ​ $ 12.00 ​ December 22, 2024 (i) 277,128 ​ $ 12.00 ​ April 13, 2025 (i) 145,686 ​ $ 12.00 ​ May 31, 2025 (i) 62,437 ​ $ 12.00 ​ February 24, 2025 ​ 172,864 ​ $ 1.27 ​ February 26, 2024 ​ 1,747,047 ​ $ 0.9535 ​ June 22, 2025 ​ 191,268 ​ $ 1.5188 ​ January 28, 2026 ​ 2,116,364 ​ $ 1.2500 ​ ​ ​ 5,129,460 ​ ​ ​ ​ ​ (i) The warrants were issued in connection with the convertible senior secured notes (see Note 8) and are classified as liabilities on the accompanying consolidated balance sheets as the warrants include cash settlement features at the option of the holders under certain circumstances. Refer to Note 4 for fair value measurements disclosures.

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Jun. 30, 2021
Stock-Based Compensation
Schedule of stock-based compensation expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended June 30, ​ Nine months ended June 30, ​ ​ 2021 2020 2021 2020 Research and development ​ $ 239,231 ​ $ 915,974 ​ $ 707,442 ​ $ 1,064,912 General and administrative ​ ​ 959,153 ​ ​ 442,746 ​ ​ 2,775,330 ​ ​ 957,824 ​ ​ $ 1,198,384 ​ $ 1,358,720 ​ $ 3,482,772 ​ $ 2,022,736
Schedule of stock option activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ ​ ​ ​ Weighted ​ Remaining ​ ​ ​ ​ ​ Number of ​ Average ​ Contractual ​ Aggregate ​ Shares Exercise Price Term (Years) Intrinsic Value Balance at October 1, 2020 ​ 3,762,143 ​ $ 2.01 ​ ​ ​ ​ ​ Granted ​ 8,461,645 ​ ​ 0.76 ​ ​ ​ ​ ​ Exercised ​ — ​ ​ — ​ ​ ​ ​ ​ Forfeited or expired ​ (113,773) ​ ​ 0.77 ​ ​ ​ ​ ​ Balance at June 30, 2021 ​ 12,110,015 ​ ​ 1.15 ​ 9.0 ​ $ 18,041,745 Vested and exercisable ​ 2,098,726 ​ ​ 1.77 ​ 8.6 ​ $ 2,673,290 Vested and expected to vest at June 30, 2021 ​ 12,110,015 ​ $ 1.15 ​ 9.0 ​ ​ ​
Schedule of option assumptions	​ ​ ​ ​ ​ ​ ​ ​ ​ Nine months ended June 30, ​ ​ ​ 2021 2020 ​ Risk-free interest rate 0.40 % 1.08 % Expected term (years) ​ 6.01 ​ 5.73 ​ Expected volatility ​ 95.4 % 89.3 % Expected dividend yield ​ — ​ — ​
Schedule of performance-based stock units activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Average ​ ​ Number ​ Base ​ Remaining ​ ​ of ​ Price ​ Contractual ​ PSUs Per PSU Term (Years) Balance at October 1, 2020 ​ 2,470 ​ $ 49.97 ​ ​ Forfeitures ​ — ​ ​ — ​ ​ Balance at June 30, 2021 ​ 2,470 ​ ​ 49.97 ​ 3.5 Vested and exercisable at June 30, 2021 ​ 2,470 ​ ​ 49.97 ​ 3.5 Vested and expected to vest at June 30, 2021 ​ 2,470 ​ $ 49.97 ​ 3.5

Liquidity (Details)

Liquidity (Details) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	Jul. 31, 2021	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020	Sep. 30, 2020
Liquidity
Debt carrying amount		$ 11,652,228	$ 11,652,228		$ 954,485
Proceeds from issuance of stock			42,514,237	$ 34,739,271
Unsecured promissory note
Liquidity
Debt carrying amount		10,734,986	10,734,986
Paycheck Protection Program
Liquidity
Debt carrying amount		$ 900,000	$ 900,000
ATM Offering
Liquidity
Number of share issued		1,207,519
Proceeds from issuance of stock		$ 3,200,000
Payment of fees to sales agent		$ 100,000
ATM Offering | Subsequent Event
Liquidity
Number of share issued	527,216
Proceeds from issuance of stock	$ 1,300,000
Payment of fees to sales agent	$ 43,000

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Basic and diluted earnings per share:
Net loss attributable to common stockholders	$ (12,196,547)	$ (3,014,867)	$ (39,758,982)	$ (38,952,142)
Basic Earnings Per Share
Weighted average shares outstanding, basic (in shares)	168,420,675	90,757,825	146,860,652	56,089,036
Net loss per share of common stock, basic (in dollars per share)	$ (0.07)	$ (0.03)	$ (0.27)	$ (0.69)
Diluted Earnings Per Share
Weighted average shares outstanding, diluted (in shares)	168,420,675	90,757,825	146,860,652	56,089,036
Net loss per share of common stock, diluted (in dollars per share)	$ (0.07)	$ (0.03)	$ (0.27)	$ (0.69)

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies - Dilutive (Details) - shares	9 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Performance-based stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	2,470	2,470
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	12,110,015	2,238,470
Common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	5,129,460	7,051,857

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($)	Jun. 30, 2021	Sep. 30, 2020
Liabilities
Warrant liability	$ 434,248	$ 70,772
Fair value measurements recurring basis | Level 3
Liabilities
Warrant liability	$ 434,248	$ 70,772

Fair Value Measurements - Chang

Fair Value Measurements - Changes in fair value (Details) - Common stock warrants	9 Months Ended
	Jun. 30, 2021USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning	$ 70,772
Change in fair value	363,476
Balance, ending	$ 434,248

Fair Value Measurements - Assum

Fair Value Measurements - Assumptions (Details)	Jun. 30, 2021USD ($)$ / shares	Sep. 30, 2020$ / sharesUSD ($)
Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant inputs	0.59	0.24
Remaining contractual term of warrant
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant inputs | $	3.6	4.4
Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant inputs	98.3	94.7
Annual dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant inputs	0	0
Fair value of common stock
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant inputs | $ / shares	2.49	0.72

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Sep. 30, 2020
Property and Equipment, Net
Laboratory equipment	$ 1,067,351		$ 1,067,351		$ 1,067,351
Less: accumulated depreciation and amortization	(862,820)		(862,820)		(740,102)
Property and equipment, net	204,531		204,531		$ 327,249
Depreciation expense	$ 40,906	$ 50,959	$ 122,718	$ 178,510

Other Assets (Details)

Other Assets (Details) - USD ($)	Jun. 30, 2021	Sep. 30, 2020
Other Assets.
Investment in PRC joint venture		$ 900,000
Other assets	$ 194,355	394,448
Total other assets	$ 194,355	$ 1,294,448

Other Assets - Additional infor

Other Assets - Additional information (Details) - USD ($)	May 22, 2020	Jun. 30, 2020	Jun. 30, 2020
Schedule of Equity Method Investments [Line Items]
Payments to Acquire Interest in Joint Venture			$ 900,000
P R C Joint Venture
Schedule of Equity Method Investments [Line Items]
Ownership percentage	20.00%
Payments to Acquire Interest in Joint Venture		$ 900,000
Expected future investment	$ 2,100,000
Contract period	4 years
Syntone | P R C Joint Venture
Schedule of Equity Method Investments [Line Items]
Ownership percentage	80.00%

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Jun. 30, 2021	Sep. 30, 2020
Accrued Expenses
Compensation	$ 452,278	$ 579,618
Severance and related costs		9,521
Research and development	2,837,663	2,890,333
Interest payable	10,454	3,691
Professional fees	43,302	132,085
Lease termination obligation		3,971,111
Other accrued expenses	148,247	170,951
Accrued expenses, total	$ 3,491,944	$ 7,757,310

Debt - Indebtedness Summary (De

Debt - Indebtedness Summary (Details) - USD ($)	Jun. 30, 2021	Nov. 05, 2020	Sep. 30, 2020
Debt Instrument [Line Items]
Debt carrying amount	$ 11,652,228		$ 954,485
Less: unamortized loan costs	(102,803)
Total debt	11,549,425		954,485
Less: current portion	(11,549,425)		(50,285)
Long-term debt			904,200
Unsecured promissory note
Debt Instrument [Line Items]
Debt carrying amount	10,734,986
Less: unamortized loan costs		$ (228,032)
Paycheck Protection Program
Debt Instrument [Line Items]
Debt carrying amount	904,200		904,200
Equipment loan
Debt Instrument [Line Items]
Debt carrying amount	$ 13,042		$ 50,285

Debt - Indebtedness - Informati

Debt - Indebtedness - Information (Details) - USD ($)	Nov. 05, 2020	May 04, 2020	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020
Debt Instrument [Line Items]
Proceeds from loan				$ 10,000,000	$ 904,200
Unamortized discount			$ 102,803	102,803
Unsecured promissory note
Debt Instrument [Line Items]
Proceeds from loan	$ 10,000,000
Original principal amount	10,200,000
Unamortized discount	$ 228,032
Debt Instrument, term	14 years
Interest rate (as a percent)	7.50%
Redemption price (as a percent)	105.00%
Interest expense			248,186	640,215
Paycheck Protection Program
Debt Instrument [Line Items]
Proceeds from loan		$ 904,200
Debt Instrument, term		2 years
Interest rate (as a percent)		1.00%
Interest expense			$ 2,279	$ 6,763

Debt - Senior Secured (Details)

Debt - Senior Secured (Details)	1 Months Ended	3 Months Ended		9 Months Ended
	Dec. 31, 2019USD ($)itemD$ / shares	Jun. 30, 2020USD ($)	Dec. 31, 2019USD ($)item	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)	Sep. 30, 2020USD ($)
Debt Instrument [Line Items]
Loss on extinguishment of debt		$ 6,164,284		$ (1,896,296)
Debt outstanding					$ 11,549,425	$ 954,485
Senior Notes
Debt Instrument [Line Items]
Interest expense		$ 269,437		$ 819,498
Old Senior notes
Debt Instrument [Line Items]
Carrying value of notes exchanged	$ 7,254,077
Interest rate (as a percent)	12.00%		12.00%
Extension fee (as a percent)	3.00%		3.00%
New Senior secured notes
Debt Instrument [Line Items]
Amount of debt as converted	$ 7,589,027
Bank exchange fee	$ 334,950		$ 334,950
Stock price threshold (as a percent)	90.00%
Number of lowest closing bid prices | item	2		2
Trading day threshold | D	20
Floor price | $ / shares	$ 0.232
Redemption feature	$ 8,264,451		$ 8,264,451
Loss on extinguishment of debt			$ (8,060,580)
Debt outstanding						$ 0
New Senior secured notes | Expected volatility
Debt Instrument [Line Items]
Redemption feature input	130		130

Debt - Unsecured Notes (Details

Debt - Unsecured Notes (Details)	Mar. 07, 2019USD ($)itemD$ / shares	Jun. 30, 2020USD ($)	Dec. 31, 2019USD ($)$ / sharesshares	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)	Sep. 30, 2020USD ($)
Debt Instrument [Line Items]
Debt outstanding					$ 11,549,425	$ 954,485
Unsecured notes
Debt Instrument [Line Items]
Original principal amount	$ 1,000,000
Debt outstanding	$ 1,947,133
Monthly stated interest rate	2.50%
Interest rate (as a percent)	12.00%
Conversion rate per share | $ / shares	$ 13.44
Stock price threshold (as a percent)	95.00%
Number of lowest closing bid prices | item	2
Trading day threshold | D	20
Carrying value of notes exchanged			$ 977,966
Accrued interest of notes exchanged			$ 570,460
Common stock issued up on conversion of stockholder notes (in shares) | shares			1,475,258
Interest expense		$ 0		$ 12,997
Unsecured notes | Weighted average
Debt Instrument [Line Items]
Conversion rate per share | $ / shares			$ 1.10

Debt - Stockholder Notes (Detai

Debt - Stockholder Notes (Details) - USD ($)	1 Months Ended	9 Months Ended
	Nov. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Sep. 30, 2020
Debt Instrument [Line Items]
Stockholder notes				$ 3,612,500
Less: current portion				(3,612,500)
Repayment of debt		$ 3,649,743	$ 35,632
Restricted stock purchase notes
Debt Instrument [Line Items]
Stockholder notes				800,000
Repayment of debt	$ 800,000
Common stock repurchase note
Debt Instrument [Line Items]
Stockholder notes				$ 2,812,500
Repayment of debt	$ 2,812,500

Commitments and Contingencies_2

Commitments and Contingencies (Details) - USD ($)	Mar. 30, 2021	Apr. 30, 2021	Jun. 30, 2021
Commitments and Contingencies.
Loss Contingency, Damages Sought, Value			$ 3,000,000
Initial settlement payment		$ 625,000
Additional payment on contingent future events	$ 750,000

Commitments and Contingencies -

Commitments and Contingencies - Lease termination (Details)	May 06, 2020USD ($)ft²	Mar. 31, 2021USD ($)	Nov. 30, 2020USD ($)	Aug. 31, 2018USD ($)	Jun. 30, 2021USD ($)	Sep. 30, 2020USD ($)
Commitment
Gain recognized					$ 552,340
Finance leases, Lease obligation					49,162	$ 72,260
Lease termination obligation						3,971,111
Corporate Office Lease, Monmouth Junction, New Jersey
Commitment
Gain recognized		$ 10,250
Corporate Office Lease, Iselin, New Jersey
Commitment
Lease term		3 years
Finance leases, Lease obligation		$ 135,535
Cranbury NJ, May 2020 lease termination
Commitment
Net rentable area | ft²	66,000
Lease termination obligation	$ 981,987					356,987
Terms of payment for lease	8 months
Cranbury NJ, August 2018 lease termination
Commitment
Gain recognized					$ 542,090
Lease termination obligation				$ 5,800,000		$ 3,971,111
Terms of payment for lease				30 months
Amount of execution of termination agreement				$ 287,615
Payment for lease per month				50,000
Lease payment in any event				4,000,000
Termination Of Lease			$ 3,250,000
Security deposit			$ 190,336	$ 174,250

Commitments and Contingencies_3

Commitments and Contingencies - Lease termination rollforward (Details)	9 Months Ended
	Jun. 30, 2021USD ($)
Leases
Balance, beginning	$ 3,971,111
Cranbury NJ, May 2020 lease termination
Leases
Balance, beginning	356,987
Cash payments	(356,987)
Cranbury NJ, August 2018 lease termination
Leases
Balance, beginning	3,971,111
Expensed accrued expense	111,315
Cash payments	(3,540,336)
Non-cash Adjustments	$ (542,090)

Commitments and Contingencies_4

Commitments and Contingencies - Lease cost (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Lease cost
Amortization of right-of-use assets		$ 32,967		$ 182,967
Interest on lease liabilities	$ 1,210	165,191	$ 3,997	903,278
Total finance lease cost	1,210	198,158	3,997	1,086,245
Operating lease cost	8,413	43,625	95,663	130,875
Total lease cost	$ 9,623	$ 241,783	$ 99,660	$ 1,217,120
Minimum
Leases
Finance lease term	12 months		12 months
Finance lease interest (as a percent)	4.00%		4.00%
Maximum
Leases
Finance lease term	36 months		36 months
Finance lease interest (as a percent)	13.00%		13.00%

Commitments and Contingencies_5

Commitments and Contingencies - Lease balance sheet (Details) - USD ($)	Jun. 30, 2021	Sep. 30, 2020
Leases
Operating leases, Right-of-use asset	$ 121,197	$ 166,986
Operating leases, Lease obligation	79,923	187,486
Finance leases, Lease obligation	$ 49,162	$ 72,260
Operating leases, Weighted-average remaining lease term	2 years 9 months 18 days	1 year
Finance leases, Weighted-average remaining lease term	1 year 10 months 24 days	2 years 4 months 24 days
Operating leases, Weighted-average discount rate (as a percent)	7.50%	9.00%
Finance leases, Weighted-average discount rate (as a percent)	9.20%	8.50%

Commitments and Contingencies_6

Commitments and Contingencies - Lease cashflow (Details) - USD ($)	9 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Leases
Operating cash flows from finance leases	$ 3,997	$ 903,278
Operating cash flows from operating leases	147,187	140,625
Financing cash flows from finance leases	23,098	$ 196,959
Right-of-use assets obtained in exchange for operating lease obligations	$ 128,473

Commitments and Contingencies_7

Commitments and Contingencies - Lease minimum payments (Details) - USD ($)	Jun. 30, 2021	Sep. 30, 2020
Operating leases
2021 (remaining three months)	$ 11,522
2022	46,652
2023	27,675
Total undiscounted lease payments	85,849
Less: Imputed interest	5,926
Total lease obligations	79,923	$ 187,486
Finance leases
2021 (remaining three months)	7,775
2022	29,605
2023	13,149
2024	4,383
Total undiscounted lease payments	54,912
Less: Imputed interest	5,750
Total lease obligations	$ 49,162	$ 72,260

Common Stock, Convertible Pre_3

Common Stock, Convertible Preferred Stock and Stockholders Equity (Deficit) - Common Stock (Details) - USD ($)	Mar. 26, 2021	Mar. 23, 2020	Jan. 27, 2020	Sep. 11, 2017	Jul. 31, 2021	Feb. 28, 2021	Jun. 30, 2020	Feb. 29, 2020	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020	Mar. 24, 2021	Mar. 23, 2021	Sep. 30, 2020	Mar. 22, 2020	Dec. 23, 2019	Apr. 12, 2019
Convertible Preferred Stock And Stockholders' Equity (Deficit) [Line Items]
Issuance of vested restricted stock units (in shares)											109
Shares of common stock issuable upon exercise of warrants									5,129,460	5,129,460
Proceeds from issuance of stock										$ 42,514,237	$ 34,739,271
Number of shares issued upon vesting of restricted stock units (in shares)											109
Common stock, shares authorized									325,000,000	325,000,000		325,000,000	200,000,000	325,000,000
Deemed Dividend, Amendment Of Series A1 Convertible Preferred Stock											$ 10,328,118
MTTR, LLC ("MTTR")
Convertible Preferred Stock And Stockholders' Equity (Deficit) [Line Items]
Number of share issued			7,244,739
Direct registered offering
Convertible Preferred Stock And Stockholders' Equity (Deficit) [Line Items]
Number of share issued							8,407,411	7,598,426
Shares of common stock issuable upon exercise of warrants							588,519	3,799,213			588,519
Shares issued, price per share							$ 1.215	$ 1.016			$ 1.215
Proceeds from issuance of stock							$ 10,200,000	$ 6,700,000
Exercise price per share							$ 1.51875				$ 1.51875
Warrants exercise term							5 years				5 years
Private Placement
Convertible Preferred Stock And Stockholders' Equity (Deficit) [Line Items]
Number of share issued						3,000,000	16,000,000	2,460,630
Shares of common stock issuable upon exercise of warrants								1,230,315
Shares issued, price per share						$ 1	$ 1	$ 1.016			$ 1
Proceeds from issuance of stock						$ 3,000,000	$ 16,000,000
Net proceeds from warrants								$ 2,500,000
Exercise price per share								$ 0.9535
Warrants exercise term								4 years
Placement Agent
Convertible Preferred Stock And Stockholders' Equity (Deficit) [Line Items]
Shares of common stock issuable upon exercise of warrants								531,890
Shares issued, price per share								$ 1.27
Warrants exercise term								5 years
Underwritten Public Offering
Convertible Preferred Stock And Stockholders' Equity (Deficit) [Line Items]
Number of share issued						38,593,767
Shares of common stock issuable upon exercise of warrants						2,116,364
Shares issued, price per share						$ 1
Proceeds from issuance of stock						$ 35,500,000
Exercise price per share						$ 1.25
Warrants exercise term						5 years
GMS Ventures & Investments
Convertible Preferred Stock And Stockholders' Equity (Deficit) [Line Items]
Number of share issued				1,013,627		8,360,000
Shares issued, price per share				$ 1
Proceeds from issuance of stock				$ 1,000,000
ATM Offering
Convertible Preferred Stock And Stockholders' Equity (Deficit) [Line Items]
Number of share issued									1,207,519
Proceeds from issuance of stock									$ 3,200,000
Aggregate offering price	$ 40,000,000
Amount reclassified on additional paid in capital	$ 197,654
Deferred costs									181,763	$ 181,763
Percentage of commission on sale of common stock	3.00%
Payment of fees to sales agent									$ 100,000
ATM Offering | Subsequent Event
Convertible Preferred Stock And Stockholders' Equity (Deficit) [Line Items]
Number of share issued					527,216
Proceeds from issuance of stock					$ 1,300,000
Payment of fees to sales agent					$ 43,000
Common stock warrants
Convertible Preferred Stock And Stockholders' Equity (Deficit) [Line Items]
Number of share issued											13,003,414
Shares of common stock issuable upon exercise of warrants							15,085,240		3,641,507	3,641,507	15,085,240
Proceeds from issuance of stock										$ 3,585,809
Exercise price per share		$ 0.232					$ 0.232		$ 0.9847	$ 0.9847	$ 0.232					$ 0.2320	$ 2.90
Series A-1 convertible preferred stock
Convertible Preferred Stock And Stockholders' Equity (Deficit) [Line Items]
Number of share issued		29,358,621
Convertible preferred stock, shares authorized									200,000	200,000				200,000
Shares issued, price per share									$ 100	$ 100
Number of stock converted		68,112
Conversion rate per share		$ 431.03447263													$ 18.89797
Deemed Dividend, Amendment Of Series A1 Convertible Preferred Stock										$ 10,328,118
Convertible preferred stock outstanding									0	0				0
Accrued dividends rate										10.00%
Preferred stock issued to settle dividends (in shares)											1,661

Common Stock, Convertible Pre_4

Common Stock, Convertible Preferred Stock and Stockholders Equity (Deficit) - Warrants summary (Details)	Jun. 30, 2021$ / sharesshares
Class of Warrant or Right [Line Items]
Shares of common stock issuable upon exercise of warrants	5,129,460
February 18, 2022
Class of Warrant or Right [Line Items]
Shares of common stock issuable upon exercise of warrants	416,666
Exercise price per share | $ / shares	$ 12
December 22, 2024
Class of Warrant or Right [Line Items]
Shares of common stock issuable upon exercise of warrants	277,128
Exercise price per share | $ / shares	$ 12
April 13, 2025
Class of Warrant or Right [Line Items]
Shares of common stock issuable upon exercise of warrants	145,686
Exercise price per share | $ / shares	$ 12
May 31, 2025
Class of Warrant or Right [Line Items]
Shares of common stock issuable upon exercise of warrants	62,437
Exercise price per share | $ / shares	$ 12
February 24, 2025
Class of Warrant or Right [Line Items]
Shares of common stock issuable upon exercise of warrants	172,864
Exercise price per share | $ / shares	$ 1.27
February 26, 2024
Class of Warrant or Right [Line Items]
Shares of common stock issuable upon exercise of warrants	1,747,047
Exercise price per share | $ / shares	$ 0.9535
June 22, 2025
Class of Warrant or Right [Line Items]
Shares of common stock issuable upon exercise of warrants	191,268
Exercise price per share | $ / shares	$ 1.5188
January 28, 2026
Class of Warrant or Right [Line Items]
Shares of common stock issuable upon exercise of warrants	2,116,364
Exercise price per share | $ / shares	$ 1.2500

Common Stock, Convertible Pre_5

Common Stock, Convertible Preferred Stock and Stockholders Equity (Deficit) - Warrants (Details) - USD ($)	9 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Mar. 23, 2020	Dec. 23, 2019	Apr. 12, 2019
Convertible Preferred Stock And Stockholders' Equity (Deficit) [Line Items]
Deemed dividend upon modification of warrants		$ 3,140,009
Shares of common stock issuable upon exercise of warrants	5,129,460
Proceeds from issuance of stock	$ 42,514,237	$ 34,739,271
Common stock warrants
Convertible Preferred Stock And Stockholders' Equity (Deficit) [Line Items]
Exercise price per share	$ 0.9847	$ 0.232	$ 0.232	$ 0.2320	$ 2.90
Shares of common stock issuable upon exercise of warrants	3,641,507	15,085,240
Proceeds from issuance of stock	$ 3,585,809
Warrants to purchase of common stock (in shares)	397,251
Warrants to purchase of common stock exercise price (in dollars per share)	$ 1.51875
Number of share issued		13,003,414
Warrant expired (in shares)		80,797
Warrants expired (in dollars per share)		$ 0.08
Warrant, 15 Months
Convertible Preferred Stock And Stockholders' Equity (Deficit) [Line Items]
Warrants exercise term				15 months
Shares of common stock issuable upon exercise of warrants		10,157,050
Warrant, 5 Years
Convertible Preferred Stock And Stockholders' Equity (Deficit) [Line Items]
Warrants exercise term				5 years

Stock-Based Compensation - Info

Stock-Based Compensation - Information (Details) - $ / shares	9 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value of the options awarded to employees	$ 0.57	$ 0.71
Performance-based stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of award	10 years
2011 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock reserved for issuance	106,490
2011 Equity Incentive Plan | Performance-based stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards outstanding	2,470
2015 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of common stock authorized for issuance	27,838,019
Number of shares available for grant	15,558,352
Term of award	10 years
2015 Equity Incentive Plan | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
2015 Equity Incentive Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years

Stock-Based Compensation - Expe

Stock-Based Compensation - Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,198,384	$ 1,358,720	$ 3,482,772	$ 2,022,736
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	239,231	915,974	707,442	1,064,912
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 959,153	$ 442,746	$ 2,775,330	$ 957,824

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock option activity (Details)	9 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares
Number of Shares
Balance, Beginning (in shares) | shares	3,762,143
Granted (in shares) | shares	8,461,645
Forfeited or expired (in shares) | shares	(113,773)
Balance, Ending (in shares) | shares	12,110,015
Vested and exercisable (in shares) | shares	2,098,726
Vested and expected to vest (in shares) | shares	12,110,015
Weighted Average Exercise Price
Balance, Beginning (in dollars per share) | $ / shares	$ 2.01
Granted (in dollars per share) | $ / shares	0.76
Forfeited or expired (in dollars per share) | $ / shares	0.77
Balance, Ending (in dollars per share) | $ / shares	1.15
Vested and exercisable (in dollars per share) | $ / shares	1.77
Vested and expected to vest (in dollars per share) | $ / shares	$ 1.15
Other option information
Balance-Remaining contractual term	9 years
Vested and exercisable-Remaining contractual term	8 years 7 months 6 days
Vested and expected to vest-Remaining contractual term	9 years
Aggregate intrinsic value | $	$ 18,041,745
Aggregate intrinsic value, Vest and exercisable | $	$ 2,673,290

Stock-Based Compensation - Opti

Stock-Based Compensation - Option Assumptions (Details) - Stock options - USD ($)	9 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	0.40%	1.08%
Expected life (years)	6 years 3 days	5 years 8 months 23 days
Expected volatility	95.40%	89.30%
Expected dividend yield	0.00%	0.00%
Unrecognized compensation expense	$ 4,988,744
Weighted average exercise period of unrecognized compensation	2 years 7 months 20 days

Stock-Based Compensation - Perf

Stock-Based Compensation - Performance-Based (Details) - Performance-based stock units	9 Months Ended
	Jun. 30, 2021$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of award	10 years
Number of PSUs
Balance, Beginning | shares	2,470
Balance, Ending | shares	2,470
Vested and exercisable | shares	2,470
Vested and expected to vest | shares	2,470
Weighted Average Base Price Per Unit
Balance, Beginning | $ / shares	$ 49.97
Vested and exercisable | $ / shares	49.97
Balance, Ending | $ / shares	49.97
Vested and expected to vest | $ / shares	$ 49.97
Weighted average remaining contractual term, Outstanding	3 years 6 months
Weighted average remaining contractual term, Vested and exercisable	3 years 6 months
Weighted average remaining contractual term, Vested and expected to vest	3 years 6 months

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted stock (Details) - USD ($)	Jan. 27, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of vested restricted stock units (in shares)					109
Stock-based compensation expense		$ 1,198,384	$ 1,358,720	$ 3,482,772	$ 2,022,736
MTTR, LLC ("MTTR")
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of share issued	7,244,739
Restricted Stock | MTTR, LLC ("MTTR")
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of share issued	7,244,739
Term following the FDA approval	6 months
Share repurchase price	$ 0.01
Number of shares vested in period				1,811,184
Grant date fair value of share	$ 0.54
Explicit service period	4 years 9 months 18 days
Stock-based compensation expense		151,764	$ 1,070,404	$ 455,293	$ 1,149,387
Unamortized expense to be recognized of stock awards other than options		$ 2,155,713		$ 2,155,713
Restricted Stock | MTTR, LLC ("MTTR") | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Repurchase right lapses on shares (as a percent)	50.00%
Restricted Stock | MTTR, LLC ("MTTR") | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Repurchase right lapses on shares (as a percent)	100.00%

Related-Party Transactions (Det

Related-Party Transactions (Details) - MTTR, LLC ("MTTR") - USD ($)	Jan. 27, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Sep. 30, 2020
Related Party Transaction [Line Items]
Shares issued during period	7,244,739
Contract termination settlement fee	$ 110,000
Related party expense		$ 271,583	$ 242,603	$ 812,808	$ 1,023,374
Due to related party, current		$ 90,476		$ 90,476		$ 89,762

Subsequent Event (Details)

Subsequent Event (Details) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	Jul. 31, 2021	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020
Subsequent Event
Proceeds from issuance of stock			$ 42,514,237	$ 34,739,271
Number of shares granted			8,461,645
Weighted average exercise price			$ 0.76
Subsequent Event
Subsequent Event
Number of shares granted	5,000,000
Weighted average exercise price	$ 2.42
ATM Offering
Subsequent Event
Number of share issued		1,207,519
Proceeds from issuance of stock		$ 3,200,000
Payment of fees to sales agent		$ 100,000
ATM Offering | Subsequent Event
Subsequent Event
Number of share issued	527,216
Proceeds from issuance of stock	$ 1,300,000
Payment of fees to sales agent	$ 43,000